Informative gene network for chemotherapy-induced peripheral neuropathy

BioData Mining

Volumn 8, Issue 1, 2015, Pages

  Reyes Gibby, Cielito C ^a   Wang, Jian ^a   Yeung, Sai Ching J ^a   Shete, Sanjay ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER G1; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR A6; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE P1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN P53; SODIUM CHANNEL NAV1.8; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ABCB1 GENE; ABCB2 GENE; ABCC2 GENE; ABCG1 GENE; ABCG2 GENE; ACYP2 GENE; AGXT GENE; ARTICLE; BCL2 GENE; BIOINFORMATICS; BTG4 GENE; CAMK2N1 GENE; CCNH GENE; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CXCL8 GENE; CYP1B1 GENE; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; DLEU7 GENE; EPHA4 GENE; EPHA5 GENE; EPHA6 GENE; ERCC1 GENE; ERK1 GENE; ERK2 GENE; FANCD2 GENE; FARS2 GENE; FGD4 GENE; FOXC1 GENE; FZD3 GENE; GENE; GENE IDENTIFICATION; GENE POOL; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC VARIABILITY; GMDS GENE; GSTM1 GENE; GSTM3 GENE; GSTP1 GENE; HUMAN; IFNG GENE; IL1B GENE; IL6 GENE; INGENUITY PATHWAY ANALYSIS; ITGA1 GENE; ITGB3 GENE; JUN GENE; KCNN3 GENE; LIMK2 GENE; LYRM4 GENE; MAPK GENE; NFKB GENE; ONCOGENE MYC; OPRM1 GENE; P38 MAPK GENE; PARP1 GENE; PELO GENE; PERIPHERAL NEUROPATHY; POU2AF1 GENE; PRIORITY JOURNAL; SCN10A GENE; SCN4A GENE; SLCO1B1 GENE; SOX10 GENE; SPIDR GENE; STAT1 GENE; STAT3 GENE; SYSTEMATIC REVIEW; TAC1 GENE; TNF GENE; TP53 GENE; TRPV1 GENE; TSPYL6 GENE; TUBB2A GENE; XKR4 GENE;

EID: 84938932615     PISSN: None     EISSN: 17560381     Source Type: Journal    
DOI: 10.1186/s13040-015-0058-0     Document Type: Article

References (104)

1. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20(6):719-25. doi: 10.1097/WCO.0b013e3282f1a06e.
2. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15(29):3081-94.
3. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17.
4. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507-15. doi: 10.1016/j.ejca.2008.04.018.
5. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain: official journal of the American Pain Society. 2009;10(11):1146-50. doi: 10.1016/j.jpain.2009.04.006.
6. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82(3):263-74.
7. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79(1):15-20.
8. Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs. 1996;51(5):713-37.
9. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology. 1994;44(5):857-61.
10. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur jneurol: the official journal of the European Federation of Neurological Societies. 2006;13(11):1153-69. doi: 10.1111/j.1468-1331.2006.01511.x.
11. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain research & management: the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur. 2007;12(1):13-21.
12. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110-8. doi: 10.1002/cncr.23008.
13. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003;1(4):274-8.
14. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 2008;9(5):505-17.
15. Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med. 2008;9(8):1209-16. doi: 10.1111/j.1526-4637.2007.00325.x.
16. Ong EC. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes. Oncology. 2008;74 Suppl 1:72-5. doi: 10.1159/000143223.
17. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109(1-2):150-61. doi: 10.1016/j.pain.2004.01.029.
18. Flatters SJ, Fox AJ, Dickenson AH. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res. 2003;984(1-2):54-62.
19. Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol. 2008;210(1):229-37. doi: 10.1016/j.expneurol.2007.11.001.
20. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol. 2008;155(7):1104-16. doi: 10.1038/bjp.2008.340.
21. Muurling T, Stankovic KM. Metabolomic and network analysis of pharmacotherapies for sensorineural hearing loss. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2014;35(1):1-6. doi: 10.1097/MAO.0000000000000254.
22. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. doi: 10.1038/nrg2918.
23. Ingenuity Pathway Analysis software. http://www.ingenuity.com/. Accessed May 2014.
24. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature. 2000;407(6804):651-4. doi: 10.1038/35036627.
25. Ingenuity Pathways Analysis (IPA) of Large Datasets. http://www.usc.edu/hsc/nml/assets/bioinfo/IPA/Data%20Analysis%20training%20Handouts.pdf. Accessed May 2014.
26. IPA Network Generation Algorithm. http://www.ingenuity.com/wp-content/themes/ingenuitytheme/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf. Accessed May 2014.
27. Stamatiou GA, Stankovic KM. A comprehensive network and pathway analysis of human deafness genes. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2013;34(5):961-70. doi: 10.1097/MAO.0b013e3182898272.
28. Doong SH, Dhruva A, Dunn LB, West C, Paul SM, Cooper BA, et al. Associations Between Cytokine Genes and a Symptom Cluster of Pain, Fatigue, Sleep Disturbance, and Depression in Patients Prior to Breast Cancer Surgery. Biol Res Nurs. 2014. doi: 10.1177/1099800414550394.
29. Oliveira A, Dinis-Oliveira RJ, Nogueira A, Goncalves F, Silva P, Vieira C, et al. Interleukin-1beta genotype and circulating levels in cancer patients: metastatic status and pain perception. Clin Biochem. 2014;47(13-14):1209-13. doi: 10.1016/j.clinbiochem.2014.04.009.
30. Stephens K, Cooper BA, West C, Paul SM, Baggott CR, Merriman JD, et al. Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery. J Pain: official journal of the American Pain Society. 2014;15(2):169-80. doi: 10.1016/j.jpain.2013.09.015.
31. Reyes-Gibby CC, Swartz MD, Yu X, Wu X, Yennurajalingam S, Anderson KO, et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support care cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2013;21(11):3117-25. doi: 10.1007/s00520-013-1885-5.
32. Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, Shete S. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage. 2013;46(2):161-72. doi: 10.1016/j.jpainsymman.2012.07.019.
33. McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, et al. Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain: official journal of the American Pain Society. 2012;13(5):425-37. doi: 10.1016/j.jpain.2011.02.358.
34. Rausch SM, Gonzalez BD, Clark MM, Patten C, Felten S, Liu H, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer. 2012;77(1):217-23. doi: 10.1016/j.lungcan.2012.02.017.
35. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009;38(6):894-902. doi: 10.1016/j.jpainsymman.2009.04.019.
36. Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, et al. The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer epidemiol, biomarkers preve: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17(11):3262-7. doi: 10.1158/1055-9965.EPI-08-0125.
37. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol. 2008;9(8):777-85. doi: 10.1016/S1470-2045(08)70197-9.
38. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med. 2005;257(2):139-55. doi: 10.1111/j.1365-2796.2004.01443.x.
39. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998;105(1):83-107.
40. Khanin R, Wit E. How scale-free are biological networks. J comput biol: a journal of computational molecular cell biology. 2006;13(3):810-8. doi: 10.1089/cmb.2006.13.810.
41. Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003;122(2):240-4.
42. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann oncol: official journal of the European Society for Medical Oncology / ESMO. 2004;15(8):1194-203. doi: 10.1093/annonc/mdh319.
43. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin cancer res: an official journal of the American Association for Cancer Research. 2006;12(10):3050-6. doi: 10.1158/1078-0432.CCR-05-2076.
44. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42(17):2893-6. doi: 10.1016/j.ejca.2006.06.017.
45. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, le Anne B, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin cancer res: an official journal of the American Association for Cancer Research. 2007;13(21):6359-68. doi: 10.1158/1078-0432.CCR-07-0660.
46. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J clin oncol: official journal of the American Society of Clinical Oncology. 2007;25(29):4528-35. doi: 10.1200/JCO.2006.10.4752.
47. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70. doi: 10.1186/1479-5876-5-70.
48. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. clin oncol: official journal of the American Society of Clinical Oncology. 2007;25(10):1247-54. doi: 10.1200/JCO.2006.08.1844.
49. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008;8:148. doi: 10.1186/1471-2407-8-148.
50. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008;99(7):1050-5. doi: 10.1038/sj.bjc.6604671.
51. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin cancer res: an official journal of the American Association for Cancer Research. 2008;14(14):4543-9. doi: 10.1158/1078-0432.CCR-07-4230.
52. Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3-4):254-6. doi: 10.1159/000236049.
53. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J clin oncol: official journal of the American Society of Clinical Oncology. 2009;27(17):2863-73. doi: 10.1200/JCO.2008.19.1718.
54. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, et al. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104(2):130-7. doi: 10.1111/j.1742-7843.2008.00351.x.
55. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113(2):264-9. doi: 10.1016/j.ygyno.2009.01.002.
56. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer. 2009;45(4):572-8. doi: 10.1016/j.ejca.2008.10.015.
57. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Anna oncol: official journal of the European Society for Medical Oncology/ESMO. 2009;20(4):736-40. doi: 10.1093/annonc/mdn698.
58. Seo BG, Kwon HC, Oh SY, Lee S, Kim SG, Kim SH, et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep. 2009;22(1):127-36.
59. Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur j neurol: the official journal of the European Federation of Neurological Societies. 2010;17(7):963-8. doi: 10.1111/j.1468-1331.2010.02966.x.
60. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J clin oncol: official journal of the American Society of Clinical Oncology. 2010;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106.
61. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 2010;101(2):530-5. doi: 10.1111/j.1349-7006.2009.01418.x.
62. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong SY. Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet. 2010;198(1):40-6. doi: 10.1016/j.cancergencyto.2009.12.004.
63. Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther. 2010;48(11):729-34.
64. Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 2010;34(2):189-93. doi: 10.1016/j.canep.2010.02.008.
65. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10(1):54-61. doi: 10.1038/tpj.2009.45.
66. Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci. 2010;25(6):846-52. doi: 10.3346/jkms.2010.25.6.846.
67. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J clin oncol: official journal of the American Society of Clinical Oncology. 2010;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943.
68. Ofverholm A, Einbeigi Z, Manouchehrpour S, Albertsson P, Skrtic S, Enerback C. The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity. Oncology letters. 2010;1(1):151-4. doi: 10.3892/ol-00000028.
69. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat. 2010;124(2):593-8. doi: 10.1007/s10549-010-1034-5.
70. Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol. 2011;67(5):1179-87. doi: 10.1007/s00280-010-1466-y.
71. Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011;67(7):693-700. doi: 10.1007/s00228-011-1007-6.
72. Bergmann TK, Brasch-Andersen C, Green H, Mirza MR, Skougaard K, Wihl J, et al. Impact of ABCB1 Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic Clin Pharmacol Toxicol. 2011. doi: 10.1111/j.1742-7843.2011.00802.x.
73. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0.
74. Cibeira MT, de Larrea CF, Navarro A, Diaz T, Fuster D, Tovar N, et al. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res. 2011;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009.
75. Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica. 2011;96(11):1728-32. doi: 10.3324/haematol.2011.041434.
76. Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics. 2011;21(3):121-9. doi: 10.1097/FPC.0b013e3283436b45.
77. Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol. 2011;67(6):1323-31. doi: 10.1007/s00280-010-1425-7.
78. Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J clin oncol: official journal of the American Society of Clinical Oncology. 2011;29(7):797-804. doi: 10.1200/JCO.2010.28.0792.
79. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 2011;11(2):121-9. doi: 10.1038/tpj.2010.13.
80. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011;130(3):993-1002. doi: 10.1007/s10549-011-1671-3.
81. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin cancer resh: an official journal of the American Association for Cancer Research. 2012;18(18):5099-109. doi: 10.1158/1078-0432.CCR-12-1590.
82. Braunagel D, Schaich M, Kramer M, Dransfeld CL, Ehninger G, Mahlknecht U. The T-T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia. Leuk Lymphoma. 2012;53(5):952-7. doi: 10.3109/10428194.2011.635862.
83. Fung C, Vaughn DJ, Mitra N, Ciosek SL, Vardhanabhuti S, Nathanson KL, et al. Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). Front Endocrinol. 2012;3:163. doi: 10.3389/fendo.2012.00163.
84. Hasmats J, Kupershmidt I, Rodriguez-Antona C, Su QJ, Khan MS, Jara C, et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene. 2012;506(1):62-8. doi: 10.1016/j.gene.2012.06.053.
85. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, et al. CYP2C8∗3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012;134(1):401-10. doi: 10.1007/s10549-012-2054-0.
86. Leandro-Garcia LJ, Leskela S, Jara C, Green H, Avall-Lundqvist E, Wheeler HE, et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin cancer res: an official journal of the American Association for Cancer Research. 2012;18(16):4441-8. doi: 10.1158/1078-0432.CCR-12-1221.
87. Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-36. doi: 10.1002/cncr.26614.
88. Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119(19):3570-7. doi: 10.1002/cncr.28234.
89. Bergmann TK, Vach W, Feddersen S, Eckhoff L, Green H, Herrstedt J, et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 2013;52(4):871-4. doi: 10.3109/0284186X.2012.707787.
90. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13(5):403-9. doi: 10.1038/tpj.2012.31.
91. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, et al. CYP3A4∗22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin cancer res: an official journal of the American Association for Cancer Research. 2013;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786.
92. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, et al. CYP2C8∗3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann oncol: official journal of the European Society for Medical Oncology / ESMO. 2013;24(6):1472-8. doi: 10.1093/annonc/mdt018.
93. Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology letters. 2013;6(3):648-54. doi: 10.3892/ol.2013.1467.
94. Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013;50(9):599-605. doi: 10.1136/jmedgenet-2012-101466.
95. Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol. 2013;71(4):843-51. doi: 10.1007/s00280-013-2075-3.
96. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. Genetic polymorphisms of ERCC1118, XRCC1399 and GSTP1105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatinbased adjuvant chemotherapy. Mol med rep. 2013;7(6):1904-11. doi: 10.3892/mmr.2013.1435.
97. McWhinney-Glass S, Winham SJ, Hertz DL, Yen Revollo J, Paul J, He Y, et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin cancer res: an official journal of the American Association for Cancer Research. 2013;19(20):5769-76. doi: 10.1158/1078-0432.CCR-13-0774.
98. Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther. 2013;51(6):475-81. doi: 10.5414/CP201851.
99. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin cancer res: an official journal of the American Association for Cancer Research. 2014;20(9):2466-75. doi: 10.1158/1078-0432.CCR-13-3232.
100. Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J clin oncol: official journal of the American Society of Clinical Oncology. 2014;32(9):949-59. doi: 10.1200/JCO.2013.53.0808.
101. Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann oncol: official journal of the European Society for Medical Oncology/ESMO. 2014;25(2):398-403. doi: 10.1093/annonc/mdt546.
102. Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, et al. Genetic heterogeneity beyond CYP2C8∗3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat. 2014;145(1):245-54. doi: 10.1007/s10549-014-2910-1.
103. Khrunin AV, Khokhrin DV, Moisseev AA, Gorbunova VA, Limborska SA. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014;15(3):329-37. doi: 10.2217/pgs.13.237.
104. Lee SY, Im SA, Park YH, Woo SY, Kim S, Choi MK, et al. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer. 2014;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028.